IRIS
BUGATTI, SERENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.285
AS - Asia 2.937
EU - Europa 2.045
SA - Sud America 443
AF - Africa 110
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 2
Totale 8.829
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.190
CN - Cina 1.129
SG - Singapore 705
IE - Irlanda 473
VN - Vietnam 420
HK - Hong Kong 361
BR - Brasile 326
RU - Federazione Russa 302
DE - Germania 270
FI - Finlandia 241
IT - Italia 183
UA - Ucraina 133
FR - Francia 127
GB - Regno Unito 98
SE - Svezia 90
IN - India 74
ZA - Sudafrica 60
CA - Canada 51
BD - Bangladesh 35
AR - Argentina 33
JP - Giappone 23
MX - Messico 23
AE - Emirati Arabi Uniti 22
CO - Colombia 21
EC - Ecuador 21
TR - Turchia 19
BE - Belgio 18
ES - Italia 18
PK - Pakistan 18
VE - Venezuela 18
ID - Indonesia 16
IQ - Iraq 16
IR - Iran 14
SA - Arabia Saudita 14
CZ - Repubblica Ceca 13
NL - Olanda 13
PL - Polonia 13
AT - Austria 10
LT - Lituania 10
MA - Marocco 10
EG - Egitto 9
MY - Malesia 9
PH - Filippine 9
UZ - Uzbekistan 9
PE - Perù 8
CL - Cile 7
KE - Kenya 7
IL - Israele 6
TH - Thailandia 6
RO - Romania 5
SK - Slovacchia (Repubblica Slovacca) 5
TN - Tunisia 5
AL - Albania 4
AU - Australia 4
BG - Bulgaria 4
BO - Bolivia 4
CR - Costa Rica 4
AZ - Azerbaigian 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
ET - Etiopia 3
GR - Grecia 3
JM - Giamaica 3
JO - Giordania 3
KG - Kirghizistan 3
KZ - Kazakistan 3
NZ - Nuova Zelanda 3
PA - Panama 3
PS - Palestinian Territory 3
SN - Senegal 3
TT - Trinidad e Tobago 3
UY - Uruguay 3
CU - Cuba 2
CY - Cipro 2
EU - Europa 2
HN - Honduras 2
HU - Ungheria 2
KR - Corea 2
KW - Kuwait 2
LK - Sri Lanka 2
NG - Nigeria 2
OM - Oman 2
PT - Portogallo 2
PY - Paraguay 2
SY - Repubblica araba siriana 2
ZM - Zambia 2
BY - Bielorussia 1
CH - Svizzera 1
CI - Costa d'Avorio 1
DK - Danimarca 1
EE - Estonia 1
HR - Croazia 1
KH - Cambogia 1
LB - Libano 1
LV - Lettonia 1
MK - Macedonia 1
MR - Mauritania 1
NA - Namibia 1
NI - Nicaragua 1
NO - Norvegia 1
Totale 8.823
Salva come PNG Salva come JPEG
Città #
Dublin 467
Chandler 415
Singapore 391
Hong Kong 348
San Jose 326
Dallas 311
Ashburn 288
Beijing 247
Jacksonville 195
Nanjing 195
Ho Chi Minh City 137
Boardman 122
Helsinki 113
Hanoi 104
Munich 102
Lauterbourg 101
New York 94
Los Angeles 84
Princeton 81
Lawrence 75
Wilmington 75
Nanchang 67
Ann Arbor 64
Shenyang 59
Shanghai 57
Medford 51
Hebei 50
Johannesburg 49
Moscow 49
Changsha 48
Da Nang 45
Redondo Beach 42
Turku 42
Buffalo 39
Milan 39
Jiaxing 36
Pavia 30
São Paulo 30
Hangzhou 25
Montreal 23
Orem 21
Tianjin 21
Tokyo 20
Dubai 19
Santa Clara 19
Brussels 18
London 18
Piscataway 18
Seattle 18
The Dalles 18
Woodbridge 18
Chennai 17
Rio de Janeiro 17
Denver 15
Toronto 15
Frankfurt am Main 14
Brooklyn 13
Columbus 13
Haiphong 12
Stockholm 12
Tabriz 12
Fairfield 11
Falkenstein 11
Norwalk 11
Nuremberg 11
Warsaw 11
Atlanta 10
Manchester 10
Poplar 10
Guangzhou 9
Mexico City 9
Baghdad 8
Belo Horizonte 8
Medellín 8
Mumbai 8
Quito 8
Washington 8
Zhengzhou 8
Amsterdam 7
Berlin 7
Chicago 7
Council Bluffs 7
Houston 7
Phủ Lý 7
Biên Hòa 6
Brno 6
Bến Tre 6
Elk Grove Village 6
Guayaquil 6
Jeddah 6
Nairobi 6
Phoenix 6
Porto Alegre 6
San Francisco 6
Tashkent 6
Verona 6
Bangkok 5
Boston 5
Cape Town 5
Caracas 5
Totale 5.757
Salva come PNG Salva come JPEG
Nome #
Assessment of synovitis to predict bone erosions in rheumatoid arthritis 149
B cells in rheumatoid arthritis. 145
Anti-neutrophil cytoplasmic antibodies (ANCA) ( Review ) [Anticorpi anticitoplasma dei neutrofili (ANCA)] 138
B cells in rheumatoid arthritis: from pathogenic players to disease biomarkers 138
In early inflammatory polyarthritis more intensive management according to the 2010 ACR/EULAR criteria leads to higher rates of clinical remission: Comparison of two cohorts treated according to different treat to target protocols 135
Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis 134
Analysis of the apolipoprotein(a) size polymorphism in patients with systemic lupus erythematosus. 127
Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis 123
Analysis of the apolipoprotein(a) size polymorphism in patients with systemic lupus erythematosus 123
Analysis of the apoliporotein(a) size polymorphism in patients with systemic lupus erythematosus 120
B cells in rheumatoid arthritis. 118
Reactogenicity, safety and disease flares following BNT162b2 mRNA COVID-19 vaccine in patients with chronic immune-inflammatory arthritis treated with biological and targeted synthetic disease-modifying anti-rheumatic drugs 117
CCL21 expression pattern of human secondary lymphoid organ stroma is conserved in inflammatory lesions with lymphoid neogenesis 114
Clinical, Imaging, and Pathological Suppression of Synovitis in Rheumatoid Arthritis: Is the Disease Curable? 111
B cell autoimmunity and bone damage in rheumatoid arthritis 110
Autoantibodies to heterogeneous nuclear ribonucleoproteins. 110
Ultrasonographic and MRI characterisation of the palindromic phase of rheumatoid arthritis 109
A Multicenter Retrospective Analysis Evaluating Performance of Synovial Biopsy Techniques in Patients With Inflammatory Arthritis: Arthroscopic Versus Ultrasound-Guided Versus Blind Needle Biopsy 108
Janus kinase inhibitors effectively improve pain across different disease activity states in rheumatoid arthritis 107
Challenges in the diagnosis of early rheumatoid arthritis in times of COVID-19 107
Correspondence on 'EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs' 106
B cell synovitis and clinical phenotypes in rheumatoid arthritis: relationship to disease stages and drug exposure 103
Subclinical remodelling of draining lymph node structure in early and established rheumatoid arthritis assessed by power Doppler ultrasonography 101
Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. 100
A case of a rheumatoid nodule on the aortic valve in a patient with rheumatoid arthritis in sustained remission with anti-TNFα 99
null 97
Adult-onset Still's disease with elderly onset, results from a multicentre study 97
What can we learn from treatment-induced changes in rheumatoid factor and anti-citrullinated peptide antibodies? 93
Established rheumatoid arthritis. The pathogenic aspects. 93
Impact of Anti-Citrullinated Protein Antibodies on Progressive Systemic Bone Mineral Density Loss in Patients With Early Rheumatoid Arthritis After Two Years of Treat-to-Target 92
Personalized Therapeutic Strategies in the Management of Osteoporosis in Patients with Autoantibody-Positive Rheumatoid Arthritis 92
Vitamin D 25OH Deficiency and Mortality in Moderate to Severe COVID-19: A Multi-Center Prospective Observational Study 90
Long term treatment of rheumatoid arthritis with rituximab 90
Inflammatory correlates of the Patient Global Assessment of Disease Activity vary in relation to disease duration and autoantibody status in patients with rheumatoid arthritis 89
No evidence of short-term impact of repeated BNT162b2 vaccination on rheumatoid arthritis homeostasis in drug-free remission 88
Nuovi aspetti patogenetici dell’artrite reumatoide 88
Subchondral Bone Marrow Inflammatory Involvement in Rheumatoid Arthritis: Lymphoid Neogenesis and In Situ Relationship with Subchondral Bone Marrow Osteoclasts 88
A “Window of Therapeutic Opportunity” for Anti-Cytokine Therapy in Patients With Coronavirus Disease 2019 88
Cytokine profile, ferritin, and multi-visceral involvement characterise macrophage activation syndrome during adult-onset Still's disease 88
Long term treatment of rheumatoid arthritis with rituximab. 87
Involvement of subchondral bone marrow in rheumatoid arthritis: lymphoid neogenesis and in situ relationship to subchondral bone marrow osteoclast recruitment 87
Treatment comparison in rheumatoid arthritis: Head-to-head trials and innovative study designs 87
B cell synovitis and clinical phenotypes in rheumatoid arthritis: relationship to disease stages and drug exposure 87
Dupilumab-induced enthesoarthritis and refractory atopic dermatitis successfully treated with baricitinib 86
Insights Into the Concept of Rheumatoid Arthritis Flare 86
Seronegative autoimmune diseases: A challenging diagnosis 84
Limiting factors to Boolean remission differ between autoantibody-positive and -negative patients in early rheumatoid arthritis 84
What can we learn from treatment-induced changes in rheumatoid factor and anti-citrullinated peptide antibodies? 83
The draining lymph node in rheumatoid arthritis: current concepts and research perspectives 83
Cost-effectiveness of the early arthritis clinic organizational model: the ELECTRA study 82
Early treatment in early undifferentiated arthritis 82
Estimated 10-year cardiovascular risk in a large Italian cohort of rheumatoid arthritis patients: Data from the Cardiovascular Obesity and Rheumatic DISease (CORDIS) Study Group 82
Synovial tissue heterogeneity and peripheral blood biomarkers 81
Polyarthrite rhumatoïde associée à un trait bêta-thalassémique : aspect clinique, sérologique et immunogénétique 81
Use of ultrasound-guided small joint biopsy to evaluate the histopathologic response to rheumatoid arthritis therapy: recommendations for application to clinical trials 79
Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline 79
Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy 78
High serum levels of CXCL13 predict lower response to csDMARDs in both ACPA-positive and ACPA-negative early rheumatoid arthritis 77
Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs 77
Synovial and serum B-cell signature of autoantibody-negative rheumatoid arthritis versus autoantibody-positive rheumatoid arthritis and psoriatic arthritis 76
Prediction of long-term drug-free outcomes in ACPA-positive and ACPA-negative rheumatoid arthritis by combined clinical and ultrasound assessment of residual disease: a 5-year prospective study 75
Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA 75
Anti-neutrophil cytoplasmic antibodies (ANCA) 74
The novel cytokine interleukin-36α is expressed in psoriatic and rheumatoid arthritis synovium 74
Power Doppler ultrasonographic assessment of the joint-draining lymph node complex in rheumatoid arthritis: a prospective, proof-of-concept study on treatment with tumor necrosis factor inhibitors. 74
Differences and similarities in rheumatology specialty training programmes across European countries 74
Tumor necrosis factor-α inhibitor-related autoimmune disorders 73
Administrative Databases and Diagnostic Therapeutic and Assistance Paths -PDTA- in the Monitoring Treatment of Rheumatoid Arthritis: The Experience of ATS Pavia 73
Clinical Features of Diabetes Mellitus on Rheumatoid Arthritis: Data from the Cardiovascular Obesity and Rheumatic DISease (CORDIS) Study Group 72
Rheumatology training experience across Europe: Analysis of core competences 72
The constitutive pattern of CCL21 production is maintained in inflammatory lesions with lymphoid neogenesis 72
Clinical Applications of Synovial Biopsy. 71
Progressive increase in time to referral and persistently severe clinical presentation over the years in autoantibody-negative patients with rheumatoid arthritis in the setting of an early arthritis clinic 71
Rheumatoid arthritis treatment: the earlier the better to prevent joint damage 70
Do we need Early Arthritis Clinics to counteract the excess of mortality in rheumatoid arthritis? 68
High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease 68
In patients with early peripheral psoriatic arthritis baseline c-reactive protein, pain and ultrasound-detected synovitis predict subsequent treatment with ts/bdmards. A retrospective analysis 68
Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry 68
Timely escalation to second-line therapies after failure of methotrexate in patients with early rheumatoid arthritis does not reduce the risk of becoming difficult-to-treat 67
Role of lymphoid chemokines in the development of functional ectopic lymphoid structures in rheumatic autoimmune diseases 67
Rheumatoid arthritis in beta-thalassemic trait: clinical, serologic and immunogenetic profile. 67
Modulating the co-stimulatory signal for T cell activation in rheumatoid arthritis: Could it be the first step of the treatment? 66
La linfoneogenesi 66
Over-expression of miR-223 in T-lymphocytes of early rheumatoid arthritis patients 66
Long-term safety of abatacept in patients with rheumatoid arthritis 64
The access route through the anatomical snuffbox in ultrasound-guided synovial biopsy of the wrist allows for a safe and effective collection of tissue samples in inflammatory arthritis 63
Evaluation of Minimally Invasive, Ultrasound-guided Synovial Biopsy Techniques by the OMERACT Filter-Determining Validation Requirements 63
Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis. 62
Tender joints in early autoantibody-negative rheumatoid arthritis: Should they be included in the scoring of joint involvement of the 2010 ACR/EULAR classification criteria? 61
Seronegative rheumatoid arthritis: one year in review 2023 61
Baseline Serum Concentrations of TRAIL in Early Rheumatoid Arthritis: Relationship with Response to Disease-modifying Antirheumatic Drugs. 60
The Clinical Value of Autoantibodies in Rheumatoid Arthritis. 60
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial 60
Autoantibody-negative rheumatoid arthritis: still a challenge for the rheumatologist 58
Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis 58
Comorbidities in the Spondyloarthritis GISEA Cohort: an average treatment effect analysis on patients treated with bDMARDs 56
Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis 56
Seronegative rheumatoid arthritis: Neglected in clinical trials, a giant in clinical practice 55
Histopathology of the synovial tissue: Perspectives for biomarker development in chronic inflammatory arthritides. 51
Inflammatory lesions in the bone marrow of rheumatoid arthritis patients: a morphological perspective 51
Totale 8.583
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.736
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.736
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202193 0 0 0 0 0 0 0 0 0 45 37 11
2021/2022362 4 3 12 14 10 26 15 23 19 8 54 174
2022/20231.352 143 103 11 86 104 126 1 72 529 20 50 107
2023/2024626 46 182 22 30 53 149 23 34 11 12 31 33
2024/20251.775 43 111 24 24 21 110 124 101 468 94 236 419
2025/20263.665 307 273 458 374 461 147 862 228 325 230 0 0
Totale 9.193